On October 21, 1993, Drs. Mitchell Creinin and Phillip Darney of the University of California at San Francisco publicized the results of their study of methotrexate as an abortifacient. The study, published in the journal Contraception, involved ten women, eight of whose pregnancies were successfully terminated. (Since the original study, more than fifty women have undergone the experimental procedure.)

The most significant aspect of the UCSF study, according to Nancy Tompkins, editor of the pro-choice newsletter Choosing Choice, is the fact that methotrexate is already on the market and FDA-approved for other purposes. Before its use as an abortifacient can be anything other than experimental, however, someone has to apply for a “supplemental indication” approval, which is generally easier to get than a new-drug approval.

Others are less optimistic than Tompkins. Thus far, no drug company has publicly requested a supplemental indication approval, and according to Wayne Koberstein, editor of Pharmaceutical Executive, “it is very unlikely that any large brand-name company will take this on.” Ironically, what may prevent methotrexate from becoming widely available for abortion is its low cost (four dollars per dose compared to two hundred dollars for RU 486). Because of this, methotrexate is unlikely to be a big profit-maker, and companies may be unwilling to risk the wrath of antiabortion groups by marketing it. Even if a company does take this chance, the drug’s approval is probably at least one or two years away.

One More Thing

And it's a big one. Mother Jones is launching a new Corruption Project to do deep, time-intensive reporting on the corruption that is both the cause and result of the crisis in our democracy.

The more we thought about how Mother Jones can have the most impact right now, the more we realized that so many stories come down to corruption: People with wealth and power putting their interests first—and often getting away with it.

Our goal is to understand how we got here and how we might get out. We're aiming to create a reporting position dedicated to uncovering corruption, build a team, and let them investigate for a year—publishing our stories in a concerted window: a special issue of our magazine, video and podcast series, and a dedicated online portal so they don't get lost in the daily deluge of headlines and breaking news.

We want to go all in, and we've got seed funding to get started—but we're looking to raise $500,000 in donations this spring so we can go even bigger. You can read about why we think this project is what the moment demands and what we hope to accomplish—and if you like how it sounds, please help us go big with a tax-deductible donation today.

We Recommend

Latest

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate